中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

未开盘 08-19 16:08:48

4.790

-0.005

-0.10%

最高4.855	最低4.750	成交量4,792万
今开4.780	昨收4.795	日振幅2.19%
总市值894.92亿	流通市值894.92亿	总股本186.83亿
成交额2.30亿	换手率0.26%	流通股本186.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":4.79,"timestamp":1787126928004,"preClose":4.795,"halted":0,"volume":47916465,"delay":0,"changeRate":-0.0010427528675703635,"floatShares":18683000000,"shares":18683000000,"eps":0.15120438127905791,"marketStatus":"未开盘","change":-0.005,"latestTime":"08-19 16:08:48","open":4.78,"high":4.855,"low":4.75,"amount":230189336,"amplitude":0.021898,"askPrice":4.79,"askSize":139000,"bidPrice":4.785,"bidSize":181000,"shortable":3,"etf":0,"ttmEps":0.15120438127905791,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":0,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":4.795,"dividendRate":0.021813,"openAndCloseTimeList":[[1787103000000,1787112000000],[1787115600000,1787126400000]],"volumeRatio":0.925426,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.3251,"impliedVolPercentile":0.1469},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2660422810","title":"中国生物制药有限公司发布新的全球品牌SBP Group，加速国际化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422810","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660422810?lang=zh_cn&edition=full","pubTime":"2026-08-19 23:02","pubTimestamp":1787151720,"startTime":"0","endTime":"0","summary":"香港2026年8月19日 /美通社/ -- 中国领先的创新驱动型制药企业中国生物制药有限公司，在中期业绩发布会上宣布推出新的全球品牌SBP Group。统一的品牌形象，体现了公司从国内领先的生物制药企业向全球创新者的战略演进。SBP Group愿联动全球合作伙伴，加速中国创新走向全球、全球创新进入中国的进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5029441_ZH29441_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5029441_ZH29441_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00BZ08YT58.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1589","BK1515","01177","BK1521","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448704","title":"中国生物制药(01177)中报观察：All in AI与全球化双引擎启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448704","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660448704?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:16","pubTimestamp":1787130988,"startTime":"0","endTime":"0","summary":"中国生物制药正在进入这样一个关键阶段。在安得卫等战略产品的生产中，AI工具在细胞培养监控与纯化风险评估中的应用，助力抗体产量提高20%，生物药制造成本下降20%，直接拉升了产品毛利。其中bepirovirsen有望成为全球首款获批的乙肝功能性治愈药物，其在B-Well系列三期临床中展现出优异的功能性治愈率。纵观2026年中报，中国生物制药正展现出一种“罕见的活力”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01177","AIPO","BK1515","IE00BZ08YS42.EUR","BK1589","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","VTHR","CHAT","QTOC","BK1521","AGIX","BK1191","ARTY","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493594","title":"中国生物制药（01177）中期股东溢利同比增长1.36% 拟派中期股息7港分","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493594","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660493594?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:02","pubTimestamp":1787130142,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药（01177）公布截至2026年6月30日止六个月业绩，股东应占溢利34.35亿元人民币，同比增长1.36%；每股基本盈利19.10人民币分。董事会宣布派中期股息每股7港分。期内营收194.44亿元人民币，同比增长10.64%。其中，创新药及对外授权总收入87.9亿元，同比增长44.3%，占总收入比例上升至45.2%。研发方面，期内集团研发总投入约3.29亿元，占集团收入约16.9%，其中约93.6%已计入损益表中。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/NzVmNzI2NGE4ZDk3NWFhOTZkNGE5Nzk4MDcyMTM1NjM3MTc0MDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NzVmNzI2NGE4ZDk3NWFhOTZkNGE5Nzk4MDcyMTM1NjM3MTc0MDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988737","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1515","BK4588","01177","IE00BZ08YS42.EUR","BK4585","BK1191","BK1521","BK1589","VIG","IE00BZ08YR35.GBP","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498904","title":"中国生物制药上半年收入194.4亿元，同比增长10.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498904","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660498904?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:55","pubTimestamp":1787129700,"startTime":"0","endTime":"0","summary":"8月19日，中国生物制药（01177）发布截至2026年6月30日止6个月的中期业绩公告。报告期内，公司收入194.4亿元，同比增长10.6%；归属于母公司持有者基本溢利33.4亿元，同比增长8.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846321537.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846321537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","BK1589","01177","IE00BZ08YS42.EUR","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135605868","title":"中国生物制药(01177)宣布派发2026年中期股息每股0.07港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135605868","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135605868?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:36","pubTimestamp":1787128578,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司（01177）8月19日公布2026年中期股息方案。董事会决定向截至2026年6月30日止六个月的普通股股东派发每股0.07港元现金股息。此次股息无需股东进一步批准。\n本次派息的除净日为2026年9月1日；股东如欲获派股息，须于2026年9月2日16时30分前将股份过户文件递交至卓佳证券登记有限公司。公司股份过户登记册将于2026年9月3日至9月4日暂停办理过户手续，记录日期为2026年9月4日。\n派息款项预计于2026年9月24日支付。公司披露，本次股息不涉及任何代扣所得税安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100481847","title":"财报前瞻｜中国生物制药营收结构稳固，本季度盈利修复待验证","url":"https://stock-news.laohu8.com/highlight/detail?id=1100481847","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100481847?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:21","pubTimestamp":1786494103,"startTime":"0","endTime":"0","summary":"中国生物制药将于2026年08月19日发布最新季度财报，市场关注创新与仿制组合的盈利质量与现金流改善节奏。中国生物制药在普药与特色仿制上具备一定产品线广度，本季度关注新中标品种放量、老品种份额维护与成本费用的协同。中国生物制药在全国范围的医院与零售渠道布局较为完善，本季度的看点在于重点省份放量与新进入医院的铺货深度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜中国生物制药营收结构稳固，本季度盈利修复待验证","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1117797293","title":"异动解读｜中国生物制药盘中上涨3.83%，贝莫苏拜单抗联合安罗替尼肺鳞癌新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1117797293","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117797293?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:33","pubTimestamp":1786325607,"startTime":"0","endTime":"0","summary":"8月10日，中国生物制药盘中上涨3.83%，报5.23港元，成交额3842.54万港元。消息面上，公司8月7日公告，旗下正大天晴自研的贝莫苏拜单抗注射液联合化疗序贯联合安罗替尼胶囊获NMPA批准上市，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌，为安罗替尼第12个获批适应症、贝莫苏拜单抗第6个获批适应症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561034","title":"中国生物制药(01177)：贝莫苏拜单抗联合化疗序贯联合安罗替尼一线治疗鳞状非小细胞肺癌新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657561034?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:00","pubTimestamp":1786100404,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药贝莫苏拜单抗注射液联合化疗序贯联合盐酸安罗替尼胶囊已获得中国国家药品监督管理局的上市批准，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌。这是安罗替尼获批的第12个适应症，是贝莫苏拜单抗获批的第6个适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1521","BK1589","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1191","01177","IPOS","BK1515","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118883034","title":"中国生物制药：NMPA批准贝莫苏拜单抗联合化疗序贯安罗替尼一线治疗肺鳞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1118883034","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118883034?lang=zh_cn&edition=full","pubTime":"2026-08-07 18:59","pubTimestamp":1786100349,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，国家药监局（NMPA）已正式批准贝莫苏拜单抗联合化疗，随后序贯安罗替尼的方案，用于一线治疗鳞状非小细胞肺癌（Sq-NSCLC）。这一突破性进展，为晚期肺鳞癌患者带来了全新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00BZ08YR35.GBP","BK1589","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","01177","BK1515","BK1521","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122425877","title":"异动解读｜中国生物制药盘中上涨3.25%，多款新药密集获批推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1122425877","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122425877?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:40","pubTimestamp":1786084849,"startTime":"0","endTime":"0","summary":"8月7日，中国生物制药盘中上涨3.25%，报5.09港元，成交额3.0亿港元。消息面上，公司近日迎来密集管线催化。8月6日，附属公司北京泰德制药第二代氟比洛芬贴剂获NMPA批准上市，该产品采用热熔胶透皮技术，贴片厚度减56%、重量降75%，透皮速率达传统产品13倍，面向中国超2亿慢性疼痛患者市场，并获四年数据保护期。此外，8月4日公司BCL-2抑制剂TQB3909片NDA获CDE受理，8月3日ADC新药TQB2102第三次获突破性治疗认定，管线进展持续兑现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药盘中上涨3.25%，多款新药密集获批推进","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682563","title":"中国生物制药：附属公司第二代氟比洛芬贴剂获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682563","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657682563?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:02","pubTimestamp":1786010520,"startTime":"0","endTime":"0","summary":"8月6日，中国生物制药（01177）发布公告，公司附属公司北京泰德制药的第二代氟比洛芬贴剂（泽普思?）已获NMPA批准上市，用于骨关节炎、肩周炎、肌肉痛等多种疼痛的消炎镇痛。第二代氟比洛芬贴剂是传统凝胶贴膏的升级产品，采用全新热熔胶透皮技术，贴片厚度减56%、重量降75%，出汗不易脱落，透皮速率可达传统产品的13倍，起效更快。中国慢性疼痛患者超2亿人，外用贴剂需求持续增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063833983028.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063833983028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ08YT58.USD","BK1191","01177","BK1589","IE00BZ08YR35.GBP","IPOS","BK1515","IE00BZ08YS42.EUR","BK1521","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110598101","title":"中国生物制药(01177)宣布第二代氟比洛芬贴剂获NMPA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1110598101","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110598101?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:21","pubTimestamp":1786008111,"startTime":"0","endTime":"0","summary":"2026年8月6日，中国生物制药有限公司发布自愿公告称，其附属公司北京泰德制药股份有限公司的国家5.1类新药第二代氟比洛芬贴剂已获中国国家药品监督管理局批准上市。公告指出，中国慢性疼痛患者超过2亿，且呈现年轻化趋势。中国生物制药已建立现代透皮技术平台及产品矩阵。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657689222","title":"中国生物制药(01177.HK)：第二代氟比洛芬贴剂获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657689222","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657689222?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:20","pubTimestamp":1786008009,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1521","01177","BK1515","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124203592","title":"中国生物制药(01177)将于2026年8月19日召开董事会 审议中期业绩及派息事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1124203592","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124203592?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:36","pubTimestamp":1786005386,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司（01177）8月6日公告称，公司董事会拟于2026年8月19日（星期三）召开会议，主要议程包括：  \n1. 审议及批准公司及其附属公司截至2026年6月30日止六个月期间的未经审计中期业绩；  \n2. 研究及考虑派发2026年中期股息（如有）。\n公告显示，公司董事会目前由11名董事组成，其中执行董事5名，分别为谢其润女士、谢炳先生、郑翔玲女士、谢承润先生及谢炘先生；独立非执行董事6名，分别为陆正飞先生、鲁红女士、张鲁夫先生、李国栋医生、陈列平博士及鲁白博士。\n公司秘书赖娟代表董事会在公告中签署并发布上述消息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656531936","title":"中国生物制药：附属公司自研TQB3909片上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2656531936","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656531936?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:37","pubTimestamp":1785836220,"startTime":"0","endTime":"0","summary":"8月4日，中国生物制药（01177）发布公告，附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB3909片已向中国国家药品监督管理局药品审评中心递交新药上市申请并获得受理。公告提到，TQB3909片用于治疗既往经过至少包含BTK抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。TQB3909片已于2026年7月被纳入优先审评审批程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608043831288326.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608043831288326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1521","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1515","BK1589","BK1191","HK0000165453.HKD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129840626","title":"中国生物制药（01177）BCL-2抑制剂TQB3909递交NDA并获CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1129840626","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129840626?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:55","pubTimestamp":1785833759,"startTime":"0","endTime":"0","summary":"2026年8月4日，中国生物制药有限公司（01177）发布自愿公告称，其附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB3909片（BCL-2抑制剂）向国家药品监督管理局药品审评中心（CDE）递交的新药上市申请（NDA）已获受理，用于治疗既往接受过至少包含BTK抑制剂在内一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656536083","title":"中国生物制药(01177.HK)：TQB3909片(BCL-2 抑制剂)新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2656536083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656536083?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:52","pubTimestamp":1785833572,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD","01177","BK1515","IE00BZ08YT58.USD","BK1191","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165633038","title":"中国生物制药（01177）ADC新药TQB2102第三次入选CDE突破性治疗名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1165633038","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165633038?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:38","pubTimestamp":1785746302,"startTime":"0","endTime":"0","summary":"2026年8月3日，中国生物制药有限公司公告称，其附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB2102「HER2双抗ADC」被中国国家药品监督管理局药品审评中心纳入突破性治疗药物名单，适应症为复发或转移性疾病阶段未接受过化疗的不可切除或转移性HER2低表达成人乳腺癌患者。这是TQB2102继 “HER2阳性早期乳腺癌新辅助治疗” 与 “HER2 IHC 3+晚期结直肠癌” 后，获得的第三项突破性治疗认定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656248463","title":"中国生物制药(01177)：TQB2102“HER2双抗ADC”第三次被CDE纳入突破性治疗药物名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2656248463","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656248463?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:37","pubTimestamp":1785746238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB2102“HER2双抗 ADC”已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物名单，用于在复发或转移性疾病阶段未接受过化疗的不可切除或转移性HER2低表达成人乳腺癌患者。这是继HER2阳性早期乳腺癌新辅助治疗、HER2 IHC 3+晚期结直肠癌之后，TQB2102获得的第三项突破性疗法认定，进一步印证了其在HER2表达实体瘤治疗领域的广泛应用潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","IE00BZ08YT58.USD","LU1223083913.SGD","BK1521","HK0000165453.HKD","LU1223082196.USD","SGDM","CDE","LU1223082519.USD","BK1589","SIL","01177","IE00BZ08YS42.EUR","BK4080","NETL","BK4017","XME","BK1515","GDXJ","ADC","BK1191","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141321862","title":"中国生物制药2026年7月股份变动月报：已发行股份减少22,065,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1141321862","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141321862?lang=zh_cn&edition=full","pubTime":"2026-08-03 12:30","pubTimestamp":1785731457,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年8月3日发布截至2026年7月31日的股份变动月报。公告显示，公司法定/注册股本维持为30,000,000,000股普通股，面值每股0.025港元，法定/注册股本总额为750,000,000港元，报告期内无增减变化。报告期末已发行股份总数为18,682,952,230股，较上月底18,705,017,230股减少22,065,000股，全部因公司于2026年7月13日回购并注销所致，其中分别在当日回购10,512,000股及11,553,000股。截至2026年7月31日，公司确认已满足香港联合交易所有限公司相关上市规则和法律法规的规定，公共持股量满足要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0274},{"period":"1month","weight":-0.0735},{"period":"3month","weight":-0.0824},{"period":"6month","weight":-0.2715},{"period":"1year","weight":-0.3401},{"period":"ytd","weight":-0.216}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.007657},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056403},{"month":3,"riseRate":0.565217,"avgChangeRate":0.046203},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020807},{"month":5,"riseRate":0.695652,"avgChangeRate":0.037978},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004739},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052342},{"month":8,"riseRate":0.391304,"avgChangeRate":-0.01224},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.014397},{"month":10,"riseRate":0.545455,"avgChangeRate":0.024699},{"month":11,"riseRate":0.5,"avgChangeRate":0.067223},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.012172}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}